NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District...
Related Questions
How will the class action lawsuit affect Unicycive Therapeutics' stock price in the short term?
What are the potential financial liabilities or settlement costs associated with the lawsuit?
Could the lawsuit trigger further regulatory scrutiny or impact Unicycive's ongoing drug development programs?